Conference Call and Webcast Scheduled for Wednesday, February 11
SAN DIEGO, Jan. 21, 2026 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on February 11, 2026. The schedule for the press release and conference call / webcast is as follows:- Q4 and Year-End 2025 Press Release: February 11, 2026 at 1:00 p.m. PT / 4:00 p.m. ET
- Q4 and Year-End 2025 Conference Call: February 11, 2026 at 1:30 p.m. PT / 4:30 p.m. ET
- Domestic Dial-In Number: 800-579-2543
- International Dial-In Number: 785-424-1789
- Conference ID: NBIX
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. SOURCE Neurocrine Biosciences, Inc.
Source link
Leave a Reply